Expert consensus document: Defining the major health modifiers causing atrial fibrillation: A roadmap to underpin personalized prevention and treatment

Nature Reviews Cardiology

Volumn 13, Issue 4, 2016, Pages 230-237

  Fabritz, Larissa ^a,b   Guasch, Eduard ^c,d   Antoniades, Charalambos ^e   Bardinet, Isabel ^f   Benninger, Gerlinde ^g   Betts, Tim R ^e   Brand, Eva ^b   Breithardt, Günter ^b,g   Bucklar Suchankova, Gabriela ^h   Camm, A John ^i,j   Cartlidge, David ^k   Casadei, Barbara ^e   Chua, Winnie W L ^a   Crijns, Harry J G M ^l,m   Deeks, Jon ^a   Hatem, Stéphane ⁿ   Hidden Lucet, Françoise ⁿ   Kääb, Stefan ^o,p   Maniadakis, Nikos ^q   Martin, Stephan ^f   Mont, Lluis ^c,d   Reinecke, Holger ^b   Sinner, Moritz F ^o   Schotten, Ulrich ^l,m   Southwood, Taunton ^a   Stoll, Monika ^l,m   Vardas, Panos ^r   Wakili, Reza ^o,p   West, Andy ^k   Ziegler, André ^h   Kirchhof, Paulus ^a,b,g,s,t   more..

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c HOSPITAL CLÍNIC   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f European Society of Cardiology   (France)

^g Atrial Fibrillation Network (AFNET) Association   (Germany)

^h Roche Professional Diagnostics   (Switzerland)

ⁱ ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

^k UK Health and Environmental Research Institute   (United Kingdom)

^l MAASTRICHT UNIVERSITY   (Netherlands)

^m MAASTRICHT UNIVERSITY   (Netherlands)

ⁿ SORBONNE UNIVERSITÉ   (France)

^o UNIVERSITY OF MUNICH   (Germany)

^p DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^q NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^r UNIVERSITY OF CRETE   (Greece)

^s SWBH NHS Trust   (United Kingdom)

^t UHB NHS Trust   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTE; AGING; ATRIAL FIBRILLATION; ATRIAL FIBROSIS; AUTONOMIC DYSFUNCTION; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CARDIOVASCULAR RISK; CELL ACTIVATION; CELL INFILTRATION; CHADS2 SCORE; CHANNELOPATHY; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DISEASE CLASSIFICATION; EXTRACELLULAR MATRIX; FAMILIAL DISEASE; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; HEART DISEASE; HEART MUSCLE CELL; HEART PROTECTION; HEREDITY; HUMAN; OBESITY; OXIDATIVE STRESS; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SINUS RHYTHM; WORKLOAD; ANIMAL; CARDIOLOGY; CONSENSUS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREDICTIVE VALUE; PREVENTIVE HEALTH SERVICE; RISK ASSESSMENT; RISK FACTOR; STANDARDS; TREATMENT OUTCOME;

ANIMALS; ATRIAL FIBRILLATION; CARDIOLOGY; CONSENSUS; HUMANS; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PREVENTIVE HEALTH SERVICES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84951320500     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2015.194     Document Type: Review

References (91)

1. Kirchhof, P., et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options. Thromb. Haemost. 106, 1012-1019 (2011
2. Marijon, E., et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing risk analysis from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study. Circulation 128, 2192-2201 (2013
3. Lip, G. Y., et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP AF) Pilot General Registry. Europace 16, 308-319 (2014
4. Kirchhof, P., et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events-European Registry in Atrial Fibrillation (PREFER in AF). Europace 16, 6-14 (2014
5. Kirchhof, P., et al. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early Treatment of Atrial Fibrillation for Stroke Prevention Trial. Am. Heart J. 166, 442-448 (2013
6. Meinertz, T., et al. Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin. Res. Cardiol. 100, 897-905 (2011
7. Bjorck, S., Palaszewski, B., Friberg, L., & Bergfeldt, L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke 44, 3103-3108 (2013
8. Haim, M., et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J. Am. Heart Assoc. 4, e001486 (2015
9. Schnabel, R. B., et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet 386, 154-162 (2015
10. Chugh, S. S., Roth, G. A., Gillum, R. F., & Mensah, G. A. Global burden of atrial fibrillation in developed and developing nations. Glob. Heart 9, 113-119 (2014
11. Camm, A. J., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 12, 1360-1420 (2010
12. January, C. T., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol. 64, e1-e76 (2014
13. Wakili, R., Voigt, N., Kaab, S., Dobrev, D., & Nattel, S. Recent advances in the molecular pathophysiology of atrial fibrillation. J. Clin. Invest. 121, 2955-2968 (2011
14. Guasch, E., et al. Atrial fibrillation promotion by endurance exercise: demonstration and mechanistic exploration in an animal model. J. Am. Coll. Cardiol. 62, 68-77 (2013
15. Sanna, T., et al. Cryptogenic stroke and underlying atrial fibrillation. N. Engl. J. Med. 370, 2478-2486 (2014
16. Boycott, H. E., et al. Shear stress triggers insertion of voltage-gated potassium channels from intracellular compartments in atrial myocytes. Proc. Natl Acad. Sci. USA 110, E3955-E3964 (2013
17. Dawson, K., et al. MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation 127, 1466-1475 (2013
18. Ellinor, P. T., et al. Meta-Analysis identifies six new susceptibility loci for atrial fibrillation. Nat. Genet. 44, 670-675 (2012
19. Kirchhof, P., et al. PITX2c is expressed in the adult left atrium, and reducing Pitx2c expression promotes atrial fibrillation inducibility and complex changes in gene expression. Circ. Cardiovasc. Genet. 4, 123-133 (2011
20. Reilly, S. N., et al. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation 124, 1107-1117 (2011
21. Schotten, U., Verheule, S., Kirchhof, P., & Goette, A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol. Rev. 91, 265-325 (2011
22. Venteclef, N., et al. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. Eur. Heart J. 36, 795-805 (2015
23. Hu, Y. F., Chen, Y. J., Lin, Y. J., & Chen, S. A. Inflammation and the pathogenesis of atrial fibrillation. Nat. Rev. Cardiol. 12, 230-243 (2015
24. Jackson, N., et al. Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/ehv213
25. Wynn, G. J., et al. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace 16, 965-972 (2014
26. Charitos, E. I., Purerfellner, H., Glotzer, T. V., & Ziegler, P. D. Clinical classifications of atrial fibrillation poorly reflect its temporal persistence: insights from 1, 195 patients continuously monitored with implantable devices. J. Am. Coll. Cardiol. 63, 2840-2848 (2014
27. Verma, A., et al. Evaluation and reduction of asymptomatic cerebral embolism in ablation of atrial fibrillation, but high prevalence of chronic silent infarction: results of the evaluation of reduction of asymptomatic cerebral embolism trial. Circ. Arrhythm. Electrophysiol. 6, 835-842 (2013
28. Pedersen, O. D., Bagger, H., Kober, L., & Torp Pedersen, C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100, 376-380 (1999
29. Vermes, E., et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107, 2926-2931 (2003
30. Disertori, M., et al. Valsartan for prevention of recurrent atrial fibrillation. N. Engl. J. Med. 360, 1606-1617 (2009
31. Goette, A., et al. Angiotensin II antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ. Arrhythm. Electrophysiol. 5, 43-51 (2012
32. Singhal, R., et al. Colchicine suppresses atrial fibrillation in failing heart. Int. J. Cardiol. 176, 651-660 (2014
33. Deftereos, S., et al. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J. Am. Coll. Cardiol. 60, 1790-1796 (2012
34. Imazio, M., et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS 2 randomized clinical trial. JAMA 312, 1016-1023 (2014
35. Antoniades, C., et al. Myocardial redox state predicts in hospital clinical outcome after cardiac surgery effects of short-Term pre-operative statin treatment. J. Am. Coll. Cardiol. 59, 60-70 (2012
36. Kirchhof, P., et al. The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. Eur. Heart J. 35, 3250-3257 (2014
37. McGann, C. J., et al. New magnetic resonance imaging-based method for defining the extent of left atrial wall injury after the ablation of atrial fibrillation. J. Am. Coll. Cardiol. 52, 1263-1271 (2008
38. Malcolme-Lawes, L. C., et al. Automated analysis of atrial late gadolinium enhancement imaging that correlates with endocardial voltage and clinical outcomes: a 2 center study. Heart Rhythm 10, 1184-1191 (2013
39. Bisbal, F., et al. CMR-guided approach to localize and ablate gaps in repeat AF ablation procedure. JACC Cardiovasc. Imaging 7, 653-663 (2014
40. Marrouche, N. F., et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA 311, 498-506 (2014
41. Andreu, D., et al. Contact force threshold for permanent lesion formation in atrial fibrillation ablation: a cardiac magnetic resonance-based study to detect ablation gaps. Heart Rhythm http://dx.doi.org/10.1016/j.hrthm.2015.08.010
42. Sramko, M., et al. Clinical value of assessment of left atrial late gadolinium enhancement in patients undergoing ablation of atrial fibrillation. Int. J. Cardiol. 179, 351-357 (2015
43. Patton, K. K., et al. N terminal pro B type natriuretic peptide as a predictor of incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis: the effects of age, sex and ethnicity. Heart 99, 1832-1836 (2013
44. Chao, T. F., et al. CHADS2 score and risk of new-onset atrial fibrillation: a nationwide cohort study in Taiwan. Int. J. Cardiol. 168, 1360-1363 (2013
45. Kirchhof, P., et al. Personalized management of atrial fibrillation: proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace 15, 1540-1556 (2013
46. Kirchhof, P., et al. Short-Term versus long-Term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 380, 238-246 (2012
47. Abed, H. S., et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 310, 2050-2060 (2013
48. Pathak, R. K., et al. Long-Term effect of goal-directed weight management in an atrial fibrillation cohort: a long-Term follow up study (LEGACY). J. Am. Coll. Cardiol. 65, 2159-2169 (2015
49. Heidbuchel, H., et al. Endurance sports is a risk factor for atrial fibrillation after ablation for atrial flutter. Int. J. Cardiol. 107, 67-72 (2006
50. Hendriks, J. M., et al. Nurse-led care versus usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care versus routine clinical care in ambulatory patients with atrial fibrillation. Eur. Heart J. 33, 2692-2699 (2012
51. Hsu, J., et al. Whole genome expression differences in human left and right atria ascertained by RNA sequencing. Circ. Cardiovasc. Genet. 5, 327-335 (2012
52. Spach, M. S., Heidlage, J. F., Dolber, P. C., & Barr, R. C. Mechanism of origin of conduction disturbances in aging human atrial bundles: experimental and model study. Heart Rhythm 4, 175-185 (2007
53. Spach, M. S., Heidlage, J. F., Dolber, P. C., & Barr, R. C. Electrophysiological effects of remodeling cardiac gap junctions and cell size: experimental and model studies of normal cardiac growth. Circ. Res. 86, 302-311 (2000
54. Spach, M. S., Dolber, P. C., & Heidlage, J. F. Interaction of inhomogeneities of repolarization with anisotropic propagation in dog atria. A mechanism for both preventing and initiating reentry. Circ. Res. 65, 1612-1631 (1989
55. Eckstein, J., et al. Time course and mechanisms of endo-epicardial electrical dissociation during atrial fibrillation in the goat. Cardiovasc. Res. 89, 816-824 (2011
56. Greiser, M., et al. Tachycardia-induced silencing of subcellular Ca2+ signaling in atrial myocytes. J. Clin. Invest. 124, 4759-4772 (2014
57. Voigt, N., et al. Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. Circulation 129, 145-156 (2014
58. Burashnikov, A., & Antzelevitch, C. Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation 107, 2355-2360 (2003
59. Heijman, J., Voigt, N., Nattel, S., & Dobrev, D. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ. Res. 114, 1483-1499 (2014
60. Christ, T., et al. Arrhythmias, elicited by catecholamines and serotonin, vanish in human chronic atrial fibrillation. Proc. Natl Acad. Sci. USA 111, 11193-11198 (2014
61. Balse, E., et al. Dynamic of ion channel expression at the plasma membrane of cardiomyocytes. Physiol. Rev. 92, 1317-1358 (2012
62. Camm, C. F., et al. Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm 10, 1661-1668 (2013
63. Eckardt, L., et al. Brugada syndrome and supraventricular tachyarrhythmias: a novel association?. J. Cardiovasc. Electrophysiol. 12, 680-685 (2001
64. Zellerhoff, S., et al. Atrial arrhythmias in long QT syndrome under daily life conditions: a nested case control study. J. Cardiovasc. Electrophysiol. 20, 401-407 (2009
65. Kirchhof, P., Zellerhoff, S., Mönnig, G., & Schulze Bahr, E. Pauses after burst pacing provoke afterdepolarizations and torsades de pointes in a patient with long QT syndrome. Heart Rhythm 1, 720-723 (2004
66. Gudbjartsson, D F., et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 448, 353-357 (2007
67. Wang, J., et al. Pitx2 prevents susceptibility to atrial arrhythmias by inhibiting left-sided pacemaker specification. Proc. Natl Acad. Sci. USA 107, 9753-9758 (2010
68. Parvez, B., et al. Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation. J. Am. Coll. Cardiol. 60, 539-545 (2012
69. Liu, L., & Nattel, S. Differing sympathetic and vagal effects on atrial fibrillation in dogs: role of refractoriness heterogeneity. Am. J. Physiol. 273, H805-H816 (1997
70. Sharifov, O. F., et al. Roles of adrenergic and cholinergic stimulation in spontaneous atrial fibrillation in dogs. J. Am. Coll. Cardiol. 43, 483-490 (2004
71. Patterson, E., Po, S. S., Scherlag, B. J., & Lazzara, R. Triggered firing in pulmonary veins initiated by in vitro autonomic nerve stimulation. Heart Rhythm 2, 624-631 (2005
72. Calvo, N., et al. Emerging risk factors and the dose-response relationship between physical activity and lone atrial fibrillation: a prospective case-control study. Europace http://dx.doi.org/10.1093/europace/euv216
73. de Vos, C. B., et al. Autonomic trigger patterns and anti-Arrhythmic treatment of paroxysmal atrial fibrillation: data from the Euro Heart Survey. Eur. Heart J. 29, 632-639 (2008
74. Shen, M. J., et al. Continuous low-level vagus nerve stimulation reduces stellate ganglion nerve activity and paroxysmal atrial tachyarrhythmias in ambulatory canines. Circulation 123, 2204-2212 (2011
75. Drca, N., Wolk, A., Jensen-Urstad, M., & Larsson, S. C. Atrial fibrillation is associated with different levels of physical activity levels at different ages in men. Heart 100, 1037-1042 (2014
76. Molina, L., et al. Long-Term endurance sport practice increases the incidence of lone atrial fibrillation in men: a follow up study. Europace 10, 618-623 (2008
77. D'Souza, A., et al. Exercise training reduces resting heart rate via downregulation of the funny channel HCN4. Nat. Commun. 5, 3775 (2014
78. Ramos, P., et al. Atrial fibrosis in a chronic murine model of obstructive sleep apnea: mechanisms and prevention by mesenchymal stem cells. Respir. Res. 15, 54 (2014
79. Katritsis, D. G., et al. Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial. J. Am. Coll. Cardiol. 62, 2318-2325 (2013
80. Nishida, K., et al. The role of pulmonary veins versus autonomic ganglia in different experimental substrates of canine atrial fibrillation. Cardiovasc. Res. 89, 825-833 (2011
81. Kim, Y. M., et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ. Res. 97, 629-636 (2005
82. Casadei, B. Statins In Cardiac Surgery Hotline. Presented at the European Society of Cardiology Congress 2014
83. Charakida, M., et al. Lifelong patterns of BMI and cardiovascular phenotype in individuals aged 60-64 years in the 1946 British birth cohort study: an epidemiological study. Lancet Diabetes Endocrinol. 2, 648-654 (2014
84. Mahajan, R., et al. Electrophysiological, electroanatomical, and structural remodeling of the atria as consequences of sustained obesity. J. Am. Coll. Cardiol. 66, 1-11 (2015
85. Thanassoulis, G., et al. Pericardial fat is associated with prevalent atrial fibrillation: the Framingham Heart Study. Circ. Arrhythm. Electrophysiol. 3, 345-350 (2010
86. Chilukoti, R. K., et al. Atrial fibrillation and rapid acute pacing regulate adipocyte/adipositas-related gene expression in the atria. Int. J. Cardiol. 187, 604-613 (2015
87. Watanabe, H., et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am. Heart J. 158, 629-636 (2009
88. Alonso, A., et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 123, 2946-2953 (2011
89. Berti, D., et al. A proposal for interdisciplinary, nurse coordinated atrial fibrillation expert programmes as a way to structure daily practice. Eur. Heart J. 34, 2725-2730 (2013
90. Stewart, S., et al. Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial. Lancet 385, 775-784 (2015
91. Kirchhof, P., et al. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace http://dx.doi.org/10.1093/europace/euv304